UNSPSC 51334306: Zuclopenthixol

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47ISU063SG. European Medicines Agency schedules Zuclopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00195MIG. Zuclopenthixol generally arises in the molecular formula C22H25CLN2OS.

UNSPSC 51334306 Zuclopenthixol is a Commodity code that nominally covers a specific antipsychotic medication, but the recent state and local opportunities associated with it show minimal alignment with the code's title. The three most recent solicitations on record target naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are zuclopenthixol or single-drug procurements. The code shows little relevant recent activity; the mismatch between the code designation and the actual scope of work posted under it suggests either data-tagging inconsistency or that zuclopenthixol itself generates infrequent solicitation volume at the state and local level.

Issuing bodies on record include a Florida county health department (Seminole County), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (Minnesota MMCAP, coordinating purchases across multiple states including Oregon). The geographic spread spans Florida, Texas, and the Upper Midwest. The one opportunity most plausibly related to pharmaceutical sourcing is the MMCAP generic pharmaceuticals RFP (due March 26, 2026), which established multiple contracts for generic drugs and OTC products through authorized wholesalers effective July 1, 2026, with a two-year term and optional extensions. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023) and the Texas HHS RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) fall outside the nominal scope. The code warrants a skip unless your firm specifically manufactures or distributes zuclopenthixol to state Medicaid programs, correction systems, or public mental-health facilities — none of which appear in the recent-opportunity record.